12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivopath tivozanib: Phase III final data

Final data from the open-label, international Phase III TIVO-1 trial in 517 patients with advanced RCC showed that once-daily 1.5 mg oral tivozanib missed the secondary endpoint of improving median OS vs. Nexavar sorafenib (28.8 vs. 29.3 months, HR=1.245, 95% CI: 0.954, 1.624, p=0.105). Patients randomized to the Nexavar arm were eligible to cross over to receive tivozanib after radiographic confirmation of disease progression, while no crossover protocol was available for patients randomized to tivozanib. Aveo said it believes that the "high" rate of utilization of second-line anti-VEGF therapy in patients following disease progression on Nexavar...

Read the full 469 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >